This study evaluated whether GM 2 ganglioside storage is necessary for neurodegeneration and neuroinflammation by performing β-hexosaminidase rescue experiments in neurons of HexB −/− mice. We developed a novel mouse model, whereby the expression of the human HEXB gene was targeted to neurons of HexB −/− mice by the Thy1 promoter. Despite β-hexosaminidase restoration in neurons was sufficient in rescuing HexB −/− mice from GM 2 neuronal storage and neurodegeneration, brain inflammation persisted, including the presence of large numbers of reactive microglia/macrophages due to persisting GM 2 presence in this cell type. In conclusion, our results suggest that neuroinflammation is not sufficient to elicit neurodegeneration as long as neuronal function is restored.
Kyrkanideset al. Journal of Neuroinflammation2012,9:186 http://www.jneuroinflammation.com/content/9/1/186
R E S E A R C H
JOURNAL OF NEUROINFLAMMATION
Open Access
Conditional expression of human βhexosaminidase in the neurons of Sandhoff disease rescues mice from neurodegeneration but not neuroinflammation 1,2* 2 3 3 4 Stephanos Kyrkanides , Sabine M Brouxhon , Ross H Tallents , Jennie H Miller , John A Olschowka 4 and M Kerry O’Banion
Abstract This study evaluated whether GM2ganglioside storage is necessary for neurodegeneration and neuroinflammation −/− by performingβhexosaminidase rescue experiments in neurons of HexB mice. We developed a novel mouse −/− model, whereby the expression of the human HEXB gene was targeted to neurons of HexB mice by the Thy1 −/− promoter. Despiteβmice from GMhexosaminidase restoration in neurons was sufficient in rescuing HexB 2 neuronal storage and neurodegeneration, brain inflammation persisted, including the presence of large numbers of reactive microglia/macrophages due to persisting GM2presence in this cell type. In conclusion, our results suggest that neuroinflammation is not sufficient to elicit neurodegeneration as long as neuronal function is restored. Keywords:GM2gangliosidosis,βhexosaminidase, Mouse, Neuron, Sandhoff disease, Transgenic
Introduction The pathognomonic feature of Sandhoff disease is GM2 ganglioside storage primarily in neurons. Catabolism of GM2ganglioside in mammalian cells is undertaken by βhexosaminidase, a lysosomal acidic hydrolase. Struc turally,βhexosaminidase (HEX) is comprised of two subunits,αandβ, and exists in three isoforms HEXA (α/βheterodimer), HEXB (β/βhomodimer) and HEXS (α/αhomodimer). In humans, HEXA (α/β) catabolizes GM2presented by a third protein named GM2activator. Each subunit,αandβ, is encoded by a distinct gene, HEXAandHEXB, located on human chromosomes 15 and 5, respectively. Human patients withHEXA(TaySachs) orHEXB(Sandhoff ) mutations develop storage of GM2 ganglioside in the lysosomes due to the lack of HEXA (α/β) enzyme activity [1]. Although HEXA enzyme is pre sent in all cell types and tissues, neurons are characterized
* Correspondence: kyrkanides@gmail.com 1 Department of Children’s Dentistry, Stony Brook University, Stony Brook, NY 118948701, USA 2 Health Science Center, Stony Brook University, Stony Brook, NY 117948701, USA Full list of author information is available at the end of the article
by remarkably higher concentrations of gangliosides than other cell types and therefore are highly susceptible to GM2lysosomal storage. Similarly to humans, two murine genes encoding forβhexosaminidase have been identified: HexAandHexB[1]. Targeted deletion of theHexAlocus resulted in the development of a mouse phenotype that showed only a mild degree of the expected pathology and lack of any neurological findings [1]. In contrast, disrup tion of the murineHexBlocus resulted in a mouse pheno type that closely resembled that of the human disease. The mice displayed storage of GM2ganglioside in the cen tral nervous system (CNS), and neurons with membran ous cytoplasmic bodies similar to those in TaySachs and Sandhoff patients [1,2]. The phenotypic variation between humans and mice appears to result from differences in the ganglioside degradation pathway between the species. It has been proposed that a second ganglioside degrad ation pathway exists in the mouse, whereby GM2can be, at least in the absence of HEXA (α/β), metabolized by a murine sialidase to asialoGM2 and subsequently catabo lized by HEXB (β/β). However, human sialidases cannot metabolize GM2ganglioside. Therefore, in the mouse HexB disruption results in GM2gangliosidosis, whereas in